XORTX Therapeutics Retained Earnings (Accumulated Deficit) 2021-2024 | XRTX

XORTX Therapeutics retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

XORTX Therapeutics Retained Earnings (Accumulated Deficit) 2021-2024 | XRTX

XORTX Therapeutics retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.6B
Takeda Pharmaceutical (TAK)$44.1B
Merck (MKKGY)$21.2B
Astellas Pharma (ALPMY)$20.4B
Sandoz Group AG (SDZNY)$19.7B
United Therapeutics (UTHR)$18B
Summit Therapeutics (SMMT)$15.6B
Neurocrine Biosciences (NBIX)$12.6B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.7B
Jazz Pharmaceuticals (JAZZ)$7.4B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$6.1B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B